Characterization of Genetically Defined ARPKD-PKHD1 Patients Enriched for Childhood/Adult Onset
Christian Hanna(Mayo Clinic), Peter C. Harris(Mayo Clinic), Tabinda Jawaid(Mayo Clinic), Fouad T. Chebib(Hypertension Institute), Sarah R. Senum(Mayo Clinic), Charles D. Madsen(Mayo Clinic), Vicente E. Torres(Mayo Clinic in Arizona), Mounif El‐Youssef(Mayo Clinic in Arizona), Maroun Chedid(Mayo Clinic)
Cited by 0
Related Papers
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
|Kidney International|2015|602
Mutations in GANAB , Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease
|The American Journal of Human Genetics|2016|463
Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca <sup>2+</sup> -permeable nonselective cation channel
|Proceedings of the National Academy of Sciences|2000|447
Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity
|Journal of Clinical Investigation|2012|444
Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease
|The American Journal of Human Genetics|2018|310